Welcome to our dedicated page for Maravai Lifesciences Holdings SEC filings (Ticker: MRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Maravai LifeSciences Holdings, Inc. filings document the formal disclosures of a Nasdaq-listed life sciences operating company with Class A common stock. Form 8-K reports furnish quarterly and annual financial results, including revenue, net loss, adjusted EBITDA and business updates for the TriLink nucleic acid synthesis and Cygnus biologics safety testing operations.
The company’s proxy materials describe annual meeting matters, director elections, independent auditor ratification, executive compensation votes and board governance. Other current reports record leadership succession, board-size and committee changes, equity-award treatment, and restructuring actions classified as exit or disposal activities, including related cost disclosures and risk language.
MIHAS CONSTANTINE S reported acquisition or exercise transactions in this Form 4 filing.
Maravai LifeSciences Holdings, Inc. director Constantine S. Mihas reported receiving a grant of 46,293 restricted stock units tied to Class A common stock at no cost on May 26, 2026. The award was made under the company’s 2020 Omnibus Incentive Plan and vests in full on the earlier of one year from grant or the 2027 annual stockholders’ meeting.
According to the disclosure, Mihas holds these securities for the benefit of a GTCR‑affiliated entity under its policies and disclaims any pecuniary interest or beneficial ownership for Section 16 purposes. Following this award, 184,348 shares or units are reported as held on behalf of the GTCR‑affiliated entity.
ECKERT R ANDREW reported acquisition or exercise transactions in this Form 4 filing.
MARAVAI LIFESCIENCES HOLDINGS, INC. director R. Andrew Eckert received an equity award of 46,293 shares of Class A common stock in the form of restricted stock units. The award was granted at no cash cost to him and represents compensation rather than an open-market purchase.
These restricted stock units were granted under the company’s 2020 Omnibus Incentive Plan and will vest in full on the earlier of one year from the May 26, 2026 grant date or the date of the company’s 2027 annual meeting of stockholders. Following this award, Eckert directly holds 412,183 shares of Class A common stock.
LUCIER GREGORY T reported acquisition or exercise transactions in this Form 4 filing.
Maravai LifeSciences director Gregory T. Lucier reported a stock-based compensation award. He received 46,293 shares of Class A Common Stock in the form of restricted stock units at a reference price of $4.38 per share under the 2020 Omnibus Incentive Plan.
The RSUs vest in full on the earlier of one year from the May 26, 2026 grant date or the 2027 annual meeting of stockholders. After this grant, Lucier directly holds 201,416 shares of Class A Common Stock and also has 109,784 shares reported as indirectly owned through a family partnership.
CUNNINGHAM SEAN LAURENCE reported acquisition or exercise transactions in this Form 4 filing.
Maravai LifeSciences Holdings reported an equity compensation grant associated with director Sean Laurence Cunningham. He was awarded 46,293 shares of Class A Common Stock in the form of restricted stock units at no cash cost. These units vest in full on the earlier of one year from the May 26, 2026 grant date or the company’s 2027 annual meeting of stockholders. The securities are held for the benefit of a GTCR-affiliated entity, and Cunningham disclaims any pecuniary interest, with reported direct holdings rising to 184,348 shares after the award.
DeFord John A reported acquisition or exercise transactions in this Form 4 filing.
MARAVAI LIFESCIENCES HOLDINGS, INC. director John A. DeFord reported an award of 46,293 shares of Class A Common Stock in the form of restricted stock units. These RSUs were granted on May 26, 2026 under the company’s 2020 Omnibus Incentive Plan and vest in full on the earlier of one year from grant or the 2027 annual meeting of stockholders. Following this grant, DeFord directly holds 205,478 shares of Class A Common Stock.
Maravai LifeSciences Holdings insider Christine Dolan acquired 5,006 shares of Class A common stock through the company’s 2020 Employee Stock Purchase Plan. The shares were acquired at a price of $1.79 per share and are reported as exempt under Rule 16b-3.
Following this transaction, Dolan directly holds 425,318 shares of Maravai Class A common stock. This filing reflects a routine, compensation-related stock purchase under an employee plan rather than an open-market trade.
Maravai LifeSciences Holdings, Inc. reported that General Counsel Kurt Oreshack acquired 776 shares of Class A Common Stock at $2.84 per share. These shares were obtained through the company’s 2020 Employee Stock Purchase Plan and the transaction was exempt under Rule 16b-3.
Following this grant/award acquisition, Oreshack directly holds a total of 385,767 shares of Class A Common Stock. This is a routine compensation-related purchase rather than an open-market buy or sale.
Maravai LifeSciences Holdings, Inc. ownership update: 12 West Capital Management and Joel Ramin report beneficial ownership of 7,260,195 shares of Class A Common Stock, representing 4.9% of the class. The percent is calculated using 146,383,162 shares outstanding as of February 19, 2026.
The statement, filed as an amendment, attributes shared voting and shared dispositive power over the reported shares to the 12 West Funds and identifies Mr. Ramin as the managing member of the reporting manager. Signatures are dated May 15, 2026.
Maravai LifeSciences Holdings, Inc. group filing amends beneficial ownership disclosure to report 13,488,799 shares of Class A common stock, representing 9.21% of the class. The filing lists the reporting group members and per-member sole voting/dispositive holdings, including Stuart Feldman with 10,337,680 shares (7.06%) and Hudson View Holdings LLC with 7,337,680 shares (5.01%). The filing is a joint Schedule 13G/A amendment signed by the group representatives on 05/14/2026.
Maravai LifeSciences Holdings, Inc. Schedule 13G filing reports that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclosed shared voting and dispositive power over 7,228,864 shares of Class A Common Stock, representing 4.9% of the class. The filing states they acquired beneficial ownership of more than 5% on May 6, 2026 and ceased to exceed 5% by the filing date. A Joint Filing Agreement dated May 11, 2026 is attached.